BlackRock
KYMR icon

BlackRock’s Kymera Therapeutics KYMR Stock Holding History

BlackRock’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$422M Buy
5,060,876
+56,781
+1% +$4.5M 0.01% 1233
2025
Q4 		$389M Buy
5,004,095
+638,647
+15% +$43.1M 0.01% 1272
2025
Q3 		$247M Buy
4,365,448
+217,188
+5% +$9.8M ﹤0.01% 1543
2025
Q2 		$181M Sell
4,148,260
-134,643
-3% -$4.64M ﹤0.01% 1684
2025
Q1 		$117M Sell
4,282,903
-73,400
-2% -$2.68M ﹤0.01% 1892
2024
Q4 		$175M Buy
4,356,303
+144,654
+3% +$6.53M ﹤0.01% 1744
2024
Q3 		$199M Buy
4,211,649
+56,220
+1% +$2.48M ﹤0.01% 1662
2024
Q2 		$124M Buy
4,155,429
+499,769
+14% +$17.3M ﹤0.01% 1902
2024
Q1 		$147M Buy
3,655,660
+89,049
+2% +$3.19M ﹤0.01% 1836
2023
Q4 		$90.8M Buy
3,566,611
+208,727
+6% +$3.73M ﹤0.01% 2135
2023
Q3 		$46.7M Buy
3,357,884
+132,038
+4% +$2.65M ﹤0.01% 2433
2023
Q2 		$74.2M Sell
3,225,846
-104,344
-3% -$2.99M ﹤0.01% 2246
2023
Q1 		$98.7M Sell
3,330,190
-4,711
-0.1% -$152K ﹤0.01% 2026
2022
Q4 		$83.2M Buy
3,334,901
+130,219
+4% +$3.47M ﹤0.01% 2121
2022
Q3 		$69.8M Buy
3,204,682
+376,248
+13% +$9.92M ﹤0.01% 2204
2022
Q2 		$55.7M Sell
2,828,434
-590,650
-17% -$13.8M ﹤0.01% 2411
2022
Q1 		$145M Buy
3,419,084
+21,544
+0.6% +$910K ﹤0.01% 1886
2021
Q4 		$216M Buy
3,397,540
+357,109
+12% +$20.8M 0.01% 1681
2021
Q3 		$179M Buy
3,040,431
+591,914
+24% +$34.3M 0.01% 1802
2021
Q2 		$119M Buy
2,448,517
+934,594
+62% +$40.6M ﹤0.01% 2152
2021
Q1 		$58.8M Buy
1,513,923
+97,292
+7% +$5.86M ﹤0.01% 2519
2020
Q4 		$87.8M Buy
1,416,631
+650,037
+85% +$31.7M ﹤0.01% 2153
2020
Q3 		$24.8M Buy
+766,594
New +$23.4M ﹤0.01% 2739

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

BlackRock's KYMR Position: Q1 2026 in Review

BlackRock increased its Kymera Therapeutics (KYMR) stake by 1.1% in Q1 2026, buying an estimated $4.5M and bringing the position to 5,060,876 shares worth $422M. The position accounts for 0.01% of the portfolio, ranked #1233.

BlackRock first reported a position in KYMR in Q3 2020 and has held it in 23 quarters since. 256 funds tracked by Wall St. Rank hold KYMR as of Q1 2026.

  • BlackRock held 5,060,876 shares of Kymera Therapeutics worth $422M as of Q1 2026.
  • BlackRock bought 56,781 Kymera Therapeutics shares in Q1 2026, an estimated $4.5M.
  • Kymera Therapeutics made up 0.01% of BlackRock's portfolio in Q1 2026, its #1233 holding.
  • BlackRock first reported a position in Kymera Therapeutics in Q3 2020 and has held it in 23 quarters since.
  • 256 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q1 2026.

Based on BlackRock's 13F filing for Q1 2026, filed 13 May 2026.